Protagen AG Establishes Scientific Advisory Board
News Dec 11, 2015
The SAB is comprised of two experienced and renowned clinical rheumatology experts; Professor Vibeke Strand, Stanford University, and Professor Matthias Schneider, Duesseldorf University.
The SAB will support the Protagen management team to address the major challenges in diagnosing and treating autoimmune diseases. In addition, the SAB will help to position Protagen as a preferred partner for drug development companies who are actively involved in the autoimmune field. Protagen can provide a range of services for such companies, including valid patient stratification, innovative companion diagnostics and novel therapy monitoring options.
"We are truly honored to welcome Vibeke and Matthias to form our SAB. We have collaborated with Matthias for a number of years, and are pleased that he will be joining forces with Vibeke”, said Dr. Stefan Muellner, Protagen CEO. “Vibeke is one of the world's leading experts in autoimmune diseases, particularly Systemic Lupus Erythematosus (SLE), and to have her on the SAB is a significant milestone in the transition of our company into the leading enabler for novel therapeutic concepts in autoimmune indications."
Professor Strand stated, “The SeroTag platform offers unique potential to support pharma and biotech companies in their clinical development programs. I’m looking forward to working with Matthias and Protagen on this exciting collaboration and am sure that together we can further advance the scientific and clinical applications of the technology”. Professor Schneider added, “I have supported Protagen for a number of years and I am still fascinated by the potential of its technology. Together with Vibeke it will be great to advance the company to the next level scientifically, clinically and commercially”.
Professor Vibeke Strand
Dr. Strand is a consultant in clinical research and regulatory affairs for pharmaceutical and biotech companies. She has been a clinical rheumatologist for 35 years - in a subspecialty practice in San Francisco, as a clinical investigator and subsequently as Director of Clinical Research at three pharmaceutical and biotech companies, prior to establishing her consulting practice in 1991. She is a member of the clinical faculty at Stanford University, serving as Adjunct Clinical Professor, Division of Immunology and Rheumatology since September 2000; Clinical Associate Professor since March 1993 and previously at University of California San Francisco.
Her professional interests include development and validation of outcome measures, and clinical development and regulatory strategies leading to approval of new agents for treatment of autoimmune diseases, including rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, gout and osteoarthritis. She has authored over 300 original publications and reviews, 50 chapters, co-edited several books and multiple proceedings. She is a Master of the American College of Rheumatology (2015), Fellow of the American College of Physicians (1982), a founding member of the Executive Committee of the International Outcome Measures in Rheumatology (OMERACT) consensus effort (1992 – present), serves on the editorial board of multiple journals, and is a member of the Cosmos Club (1994).
Professor Matthias Schneider
Professor Schneider is head of the Rheumatology Clinic, The Hiller Research Unit at Heinrich-Heine-University in Duesseldorf and Rhein-Ruhr, The Cooperation Multipurpose Arthritis Center. He is qualified within internal medicine, rheumatology, physical therapy and endocrinology and has been working in this field now for more than 30 years. In 1988, he was awarded the Venia Legendi for Internal Medicine. In research, his major topics are systemic connective tissue diseases, patient reported outcomes and risk stratification of inflammatory rheumatic diseases.
From 2013-2014, he was president of the German Society of Rheumatology, and is still leading the development of guidelines for rheumatic diseases. He represented the German rheumatology in the EULAR recommendations for various topics in SLE. For more than 20 years he supported the German SLE patient group as board member, and is medical advisor of Lupus Europe since 2004.
A simple blood test reliably detects signs of brain damage in people on the path to developing Alzheimer’s disease – even before they show signs of confusion and memory loss, according to a new study from Washington University School of Medicine in St. Louis and the German Center for Neurodegenerative Diseases in Germany.READ MORE
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019